FDA Approves New Alzheimer’s Treatment From Eli Lilly
WASHINGTON DC - The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows









